Cytomegalovirus prophylaxis with letermovir in pediatric (birth to
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00420-25 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Andreas H Groll und 14 weiteren Autor:innen. Beteiligte Einrichtung: University Children's Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Acetates, Antiviral Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC.
Abstract (Originalsprache)
Letermovir, a cytomegalovirus (CMV) terminase complex inhibitor, was first approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic cell transplant (HCT) recipients (R+). This study evaluated the pharmacokinetics (PK), efficacy, and safety of letermovir in pediatric R+ allogeneic HCT recipients. In this Phase 2b, single-arm, open-label study, 65 participants were enrolled sequentially in three age groups (AG; AG1, 12 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Children's Hospital Münster, Münster, Germany.
- Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
- Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
- Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
- Queensland Children's Hospital, Brisbane, Queensland, Australia.
- Charité Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Andreas H Groll
Förderung
- Merck Sharp & Dohme LLC
Zitieren
APA
Groll, A. H., Danziger-Isakov, L., Gefen, A., Fraser, C. J., Schulte, J. H., Bielorai, B., Karras, N. A., Bueno, D., Shaw, P. J., Broyde, N., Haber, B., Gilbert, C. L., Patel, M., McCrea, J. B., & Badshah, C. (2025). Cytomegalovirus prophylaxis with letermovir in pediatric (birth to. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00420-25
Vancouver
Groll AH, Danziger-Isakov L, Gefen A, Fraser CJ, Schulte JH, Bielorai B, et al. Cytomegalovirus prophylaxis with letermovir in pediatric (birth to. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00420-25
BibTeX
@article{Groll2025,
author = {Groll, Andreas H and Danziger-Isakov, Lara and Gefen, Aharon and Fraser, Christopher J and Schulte, Johannes H and Bielorai, Bella and Karras, Nicole A and Bueno, David and Shaw, Peter J and Broyde, Natalya and Haber, Barbara and Gilbert, Christopher L and Patel, Mayankbhai and McCrea, Jacqueline B and Badshah, Cyrus},
title = {Cytomegalovirus prophylaxis with letermovir in pediatric (birth to},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00420-25}
}
EUVIMED